期刊文献+

高通量血液透析联合血液透析滤过对慢性肾脏病患者甲状旁腺激素和钙磷水平的影响

Effect of High Throughput Hemodialysis Combined with Hemodialysis Filtration on Parathyroid Hormone and Calcium and Phosphorus Levels in Patients with Chronic Kidney Disease
下载PDF
导出
摘要 目的:评估高通量血液透析联合血液透析滤过对慢性肾脏病患者甲状旁腺激素(PTH)和钙磷水平的影响。方法:选取2021年1月—2022年2月于汕尾逸挥基金医院血液透析室接受规律血液净化治疗的慢性肾脏病患者40例作为研究对象,随机分为试验组和对照组,各20例。对照组采用常规血液透析治疗,试验组采用高通量血液透析联合血液透析滤过治疗。比较两组血钙、血磷、PTH水平及治疗效果。结果:治疗前,两组血磷、血钙及PTH水平比较,差异无统计学意义(P>0.05);治疗6个月、1年后,两组血磷、血钙及PTH水平均降低,试验组血磷、PTH水平低于对照组,血钙水平高于对照组,差异有统计学意义(P<0.05)。治疗6个月、1年后,试验组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论:高通量血液透析联合血液透析滤过治疗慢性肾脏病效果较好,可降低PTH水平,有助于钙磷代谢平衡。 Objective:To evaluate the effects of high throughput hemodialysis combined with hemodialysis filtration on parathyroid hormone(PTH)and calcium and phosphorus levels in patients with chronic kidney disease.Methods:A total of forty patients with chronic kidney disease who received regular hemodialysis treatment in the hemodialysis room of Shanwei Yihui Fund Hospital from January 2021 to February 2022 were selected as the study objects and randomly divided into experimental group and control group,with 20 cases in each group.The control group received conventional hemodialysis treatment,and the experimental group received high throughput hemodialysis combined with hemodialysis filtration treatment.The levels of blood calcium,blood phosphorus,PTH and the therapeutic effect were compared between the two groups.Results:Before treatment,there was no significant difference in blood phosphorus,blood calcium and PTH levels between the two groups(P>0.05);after 6 months and 1 year of treatment,the levels of blood phosphorus,blood calcium and PTH were decreased in both groups,and the levels of blood phosphorus and PTH in experimental group were lower than those in control group,while the levels of blood calcium were higher than those in control group,with statistical significance(P<0.05).After 6 months and 1 year of treatment,the total effective rate of experimental group was higher than that of control group,and the difference was statistically significant(P<0.05).Conclusion:High throughput hemodialysis combined with hemodialysis filtration is effective in the treatment of chronic kidney disease,which can reduce the level of PTH and contribute to the balance of calcium and phosphorus metabolism.
作者 施展跃 周佩茹 林丽君 Shi Zhanyue;Zhou Peiru;Lin Lijun(Third Department of Internal Medicine,Shanwei Yihui Fund Hospital,Shanwei 516600,Guangdong Province,China)
出处 《中外医药研究》 2024年第11期76-78,共3页 JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
基金 汕尾市科技计划项目(编号:220525166342042)。
关键词 高通量血液透析 血液透析滤过 甲状旁腺激素 血磷 High throughput hemodialysis Hemodialysis filtration Parathyroid hormone Blood phosphorus
  • 相关文献

参考文献7

二级参考文献84

  • 1张鹏,徐又佳,赵东阳,王冰,马勇,钱忠明,柯亚.铁调素对人成骨细胞(hFOB1.19)内钙离子转运的影响[J].苏州大学学报(医学版),2008,28(1):14-15. 被引量:13
  • 2徐又佳,钱忠明,俞晨.铁调素(Hepcidin)在骨质矿化中的作用[J].中国骨质疏松杂志,2005,11(4):541-543. 被引量:16
  • 3Rodriguez M, Lopez 1, Munoz J, et al. FGF'23 and mineral metab- olism, implications in CKD - MBD [ J]. Nefrologia, 2012, 32: 275 - 278.
  • 4Zhang S, Gillihan R, He N, et al. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease [ J ]. Kidney Int,2013:194.
  • 5Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 ( FGF23 ) predicts progression of chronic Kidney disease : the Mild to Moderate Kidney Disease (MMKD) Study[J]. J Am Soc Neph- ro1,2007,18:2600 - 2608.
  • 6Isakova T, Washl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic Kidney disease[J]. Kidney Int,2011,79:1370 - 1378.
  • 7Canalejo R, Canalejo A, Martinez - Moreno JM, et al. FGF23 fails to inhibit uremic parathyroid glands [ J ]. J Am Soc Nephrol, 2010,21:1125 - 1135.
  • 8Wesseling - Perry K, Pereira RC, Wang I-I, et al. Relationship between plasma fibroblast growth factor - 23 concentration and bone mineralization in children with renal failure on peritoneal dialysis [J]. J Clin Endocrinol Metab, 2009, 94:511 -517.
  • 9Kanda E, Yoshida M, SasaKlotho S. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic Kidney disease - mineral bone disease in elderly chronic Kidney disease patients[ J]. BMC Nephrol, 2012,13 : 122. O.
  • 103Neill WC, Lomashvili KA. Recent progress in the treatment of vascular calcification[ J]. Kidney Int,2010,78 : 1232 - 1239.

共引文献277

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部